Calidi Biotherapeutics Inc. (CLDI) - Net Assets
Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) has net assets worth $3.76 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.86 Million) and total liabilities ($5.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Calidi Biotherapeutics Inc. (CLDI) total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.76 Million |
| % of Total Assets | 42.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Calidi Biotherapeutics Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Calidi Biotherapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore CLDI total assets for the complete picture of this company's asset base.
Annual Net Assets for Calidi Biotherapeutics Inc. (2020–2025)
The table below shows the annual net assets of Calidi Biotherapeutics Inc. from 2020 to 2025. For live valuation and market cap data, see CLDI company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.76 Million | +91.01% |
| 2024-12-31 | $1.97 Million | +123.90% |
| 2023-12-31 | $-8.23 Million | +83.67% |
| 2022-12-31 | $-50.44 Million | -123.08% |
| 2021-12-31 | $-22.61 Million | -0.58% |
| 2020-12-31 | $-22.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Calidi Biotherapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10718400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.03% |
| Other Comprehensive Income | $-13.00K | -0.35% |
| Other Components | $145.39 Million | 3867.84% |
| Total Equity | $3.76 Million | 100.00% |
Calidi Biotherapeutics Inc. Competitors by Market Cap
The table below lists competitors of Calidi Biotherapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
$2.69 Million |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
$2.69 Million |
|
NORTHERN SHIELD RES INC.
F:N9SA
|
$2.69 Million |
|
Bathurst Metals Corp
V:BMV
|
$2.70 Million |
|
Olivers Real Food Ltd
AU:OLI
|
$2.68 Million |
|
Purple Biotech
NASDAQ:PPBT
|
$2.68 Million |
|
ZIMI Ltd
AU:ZMM
|
$2.68 Million |
|
Valion Bio Inc
NASDAQ:VBIO
|
$2.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Calidi Biotherapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,534,000 to 3,759,000, a change of 2,225,000 (145.0%).
- Net loss of 19,906,000 reduced equity.
- Dividend payments of 5,673,000 reduced retained earnings.
- New share issuances of 16,654,000 increased equity.
- Other comprehensive income increased equity by 15,000.
- Other factors increased equity by 11,135,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.91 Million | -529.56% |
| Dividends Paid | $5.67 Million | -150.92% |
| Share Issuances | $16.65 Million | +443.04% |
| Other Comprehensive Income | $15.00K | +0.4% |
| Other Changes | $11.13 Million | +296.22% |
| Total Change | $- | 145.05% |
Book Value vs Market Value Analysis
This analysis compares Calidi Biotherapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-7.54 | $0.18 | x |
| 2021-12-31 | $-94.76 | $0.18 | x |
| 2022-12-31 | $-714.54 | $0.18 | x |
| 2023-12-31 | $-58.75 | $0.18 | x |
| 2024-12-31 | $2.31 | $0.18 | x |
| 2025-12-31 | $0.87 | $0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Calidi Biotherapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -529.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.36x
- Recent ROE (-529.56%) is below the historical average (-328.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.69 Million |
| 2021 | 0.00% | -2434.97% | 0.13x | 0.00x | $-8.67 Million |
| 2022 | 0.00% | -56504.44% | 0.02x | 0.00x | $-20.38 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.39 Million |
| 2024 | -1443.48% | 0.00% | 0.00x | 9.25x | $-22.30 Million |
| 2025 | -529.56% | 0.00% | 0.00x | 2.36x | $-20.28 Million |
Industry Comparison
This section compares Calidi Biotherapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,624,003
- Average return on equity (ROE) among peers: -53.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Calidi Biotherapeutics Inc. (CLDI) | $3.76 Million | 0.00% | 1.36x | $2.68 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $67.72 Million | -21.45% | 0.18x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $18.59 Million | -164.77% | 1.78x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.61 Billion |
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast ca… Read more